ERIS Lifesciences for 25% gains
Date: 3 Dec’24
Symbol: ERIS
Timeframe: Weekly
ERIS Lifesciences currently seems to be in Wave V of 3 which is heading towards 1960-70 (25% from current price of 1470) as seen in the chart. Wave 4 could then correct back to 1300 levels.
The company, in the recently announced September quarter results has posted best ever revenues and operating profits.
This is not a prediction but a possible wave count. This is also not a recommendation to trade or invest. Please do your own analysis.
HINGLISH VERSION
ERIS Lifesciences vartamaan mein Wave 3 ki V mein dikh rahee hai jo 1960-70 (vartamaan keemat 1470 se 25%) kee taraf badh rahee hai jaisa ki chart mein dekh sakte hain. Wave 4 phir 1300 ke star tak neeche aa sakta hai.
Company ne haal hee mein ghoshit September quarter results mein ab tak ka sabse achchha revenue aur operating profit darj kiya hai.
Yah koi prediction nahin balki sambhaavit Wave count hai. Yah trade lene ya invest karne ki bhi salaah nahi hai. Kripya apana vishleshan khud karein.
Symbol: ERIS
Timeframe: Weekly
ERIS Lifesciences currently seems to be in Wave V of 3 which is heading towards 1960-70 (25% from current price of 1470) as seen in the chart. Wave 4 could then correct back to 1300 levels.
The company, in the recently announced September quarter results has posted best ever revenues and operating profits.
This is not a prediction but a possible wave count. This is also not a recommendation to trade or invest. Please do your own analysis.
HINGLISH VERSION
ERIS Lifesciences vartamaan mein Wave 3 ki V mein dikh rahee hai jo 1960-70 (vartamaan keemat 1470 se 25%) kee taraf badh rahee hai jaisa ki chart mein dekh sakte hain. Wave 4 phir 1300 ke star tak neeche aa sakta hai.
Company ne haal hee mein ghoshit September quarter results mein ab tak ka sabse achchha revenue aur operating profit darj kiya hai.
Yah koi prediction nahin balki sambhaavit Wave count hai. Yah trade lene ya invest karne ki bhi salaah nahi hai. Kripya apana vishleshan khud karein.
Related publications
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.